logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Alkem Laboratories Ltd

Alkem Laboratories

Large Cap17,432 EmployeesIPO 2015
Current Price
5544.50
-72 (-1.28%)Updated
NSE :ALKEM
BSE :539523
Today's Range
5514.5
5544.50
indicator
5665
52 Week Range
52W Low4610.00
52W High5933.50
5544.50
indicator
Downside20.27%
Upside7.02%

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
65,214.34 Cr
Market Cap
Total market value of company
P/E Ratio
27.50
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
4.86
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
198.32
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
8.46%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
20.40%
ROCE
Return on Capital Employed. >15% is good
Net Margin
16.64%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
14.03%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
9.21%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
11.20%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
19.90%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.12
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
1002.37
Book Value
Net asset value per share
Dividend Yield
0.83%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
51.20%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • Robust Return on Equity (ROE) of 19.4% demonstrates efficient shareholder utilization.
  • Healthy Return on Capital Employed (ROCE) of 20.4% indicates strong operational efficiency.

Weaknesses

4 points
  • Promoter holding decreased from 57.14% to 51.20%, indicating reduced confidence.
  • Current P/E ratio of 29.10 is slightly above the sector average.

Opportunities

4 points
  • Increasing FII and DII holdings signal growing institutional investor confidence.
  • Robust pharmaceutical sector growth presents significant expansion opportunities globally.

Threats

4 points
  • Intense competition from major players challenges market share and pricing power.
  • Strict, evolving regulatory landscapes could increase compliance costs and operational disruptions.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R45935.83+₹391.33+7.06%
R35785.33+₹240.83+4.34%
R25725.17+₹180.67+3.26%
R15634.83+₹90.33+1.63%
PIVOT5574.6730.170.54%
CURRENT5544.50--
S15183.33-₹361.17-6.51%
S25333.83-₹210.67-3.80%
S35424.17-₹120.33-2.17%
S45484.33-₹60.17-1.09%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
1.48L
(11 Mar 2026)
+13.5% vs avg
Delivery %
57.8%
(11 Mar 2026)
+7.7% vs avg
Avg Volume (20D)
1.30L
(11 Feb - 11 Mar)
20-day average
Avg Delivery %
50.1%
(11 Feb - 11 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
ABBOTINDIA
Abbott India Ltd
AJANTPHARM
Ajanta Pharma Ltd
AUROPHARMA
Aurobindo Pharma Ltd
CIPLA
Cipla Ltd
DRREDDY
Dr Reddys Laboratories Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
LAURUSLABS
Laurus Labs Ltd
LUPIN
Lupin Ltd
MANKIND
Mankind Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
TORNTPHARM
Torrent Pharmaceuticals Ltd
ZYDUSLIFE
Zydus Lifesciences Ltd

About

ALKEM

Alkem Laboratories Ltd

Alkem Laboratories Limited is a multinational pharmaceutical company with a significant presence in India, the United States, and other international markets. Its core business revolves around the research, development, manufacturing, and sale of a diverse range of pharmaceutical and nutraceutical products. This broad portfolio allows them to cater to a wide spectrum of healthcare needs.

A major component of Alkem's business is the production and distribution of branded generic and generic drugs. These medications cover a wide range of therapeutic areas, including anti-infectives to combat infections, gastro-intestinal medications for digestive issues, pain relievers (analgesics), anti-diabetic treatments, drugs targeting the neuro/central nervous system, gynecological medications, respiratory treatments, dermatological products for skin conditions, and cardiac medications for heart health. This broad therapeutic reach underscores the company's commitment to comprehensive healthcare solutions.

Beyond branded and generic drugs, Alkem also manufactures and supplies active pharmaceutical ingredients (APIs). APIs are the fundamental building blocks of many medications, and their production represents a crucial aspect of the pharmaceutical supply chain. Alkem's involvement in API manufacturing strengthens its vertical integration within the industry and allows for greater control over the quality and supply of its finished products.

Furthermore, Alkem is venturing into the burgeoning biosimilars market. Biosimilars are similar to biologic drugs but are produced by different manufacturers, offering a potentially more affordable alternative. This expansion highlights Alkem's strategic focus on innovation and its commitment to providing cost-effective treatment options to patients.

Rounding out its offerings, Alkem produces and markets a range of nutraceuticals, which are products that provide health benefits beyond basic nutrition. This includes vitamins, minerals, and nutrients, as well as over-the-counter consumer products such as mouthwash, shampoos, pregnancy detection kits, and condoms. This diversification broadens their market reach and caters to a wider consumer base.

Established in 1973 and headquartered in Mumbai, India, Alkem Laboratories Limited has built a substantial presence in the global pharmaceutical landscape. Their multifaceted business strategy, encompassing a diverse range of products and therapeutic areas, positions them for continued growth and success in the competitive pharmaceutical industry.

COMPANY FACTS - ALKEM

Registered Address

Devashish Building, Alkem House, Senapati Bapat Road, Lower Parel

Mumbai

MAHARASHTRA

IN

Tel: 912239829999

Website:https://www.alkemlabs.com/

Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 17,432

IPO Date: 23/12/2015

MANAGEMENT - ALKEM

Mr. Basudeo Singh

Executive Chairman of the Board

Dr. Vikas Gupta

Chief Executive Officer

Mr. Nitin Agrawal

President - Finance, Chief Financial Officer

Mr. Manish Narang

President - Legal, Chief Compliance Officer, Company Secretary

Mr. Sandeep Singh

Managing Director, Executive Director

Mrs. Madhurima Singh

Executive Director

Mr. Mritunjay Singh

Executive Director

Mr. Sarvesh Singh

Executive Director

Mr. Srinivas Singh

Executive Director

Mr. Narendra Aneja

Independent Director

Ms. Neela Bhattacherjee

Independent Director

Mr. Diwakar Gupta

Independent Director

Investor Questions Answered

Alkem Laboratories Ltd (ALKEM) Stock FAQs

Get answers to the most common questions about Alkem Laboratories Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Alkem Laboratories Ltd (ALKEM) is ₹5,544.5. Today, the stock has declined by ₹72.00 (1.28%), trading in a range of ₹5,514.5 to ₹5,665. The stock opened at ₹5,662 with a trading volume of 1,47,779 shares.
Alkem Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹65,214.34 crores, P/E ratio of 27.50, ROE of 8.46%, and ROCE of 20.40%. The dividend yield stands at 0.83%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Alkem Laboratories Ltd (ALKEM) is ₹5,933.5, while the 52-week low is ₹4,610. Currently trading at ₹5,544.5, the stock is 70.6% away from its 52-week low and 6.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Alkem Laboratories Ltd stock at ₹5,544.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.50 and P/B ratio of N/A. Today's performance shows a loss of 1.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Alkem Laboratories Ltd offers a dividend yield of 0.83%, which means for every ₹100 invested at the current price of ₹5,544.5, you can expect to receive approximately ₹0.83 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Alkem Laboratories Ltd's key financial metrics include: P/E Ratio: 27.50, P/B Ratio: N/A, ROE: 8.46%, ROCE: 20.40%, Dividend Yield: 0.83%, EPS: ₹198.32, Book Value: ₹1,002.37, Debt-to-Equity: 0.12, and Current Ratio: N/A. The company's market cap stands at ₹65,214.34 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Alkem Laboratories Ltd stock opened at ₹5,662 and is currently trading at ₹5,544.5, showing a decline of ₹72.00 (1.28%). The intraday high is ₹5,665 and low is ₹5,514.5. The trading volume stands at 1,47,779 shares, indicating moderate market participation today.
Alkem Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 27.50, which means investors are willing to pay ₹27.50 for every ₹1 of earnings. With an EPS of ₹198.32, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Alkem Laboratories Ltd has a market capitalization of ₹65,214.34 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹5,544.5) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Alkem Laboratories Ltd has a book value of ₹1,002.37 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹5,544.5, which is 453.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Alkem Laboratories Ltd has a Return on Equity (ROE) of 8.46% and Return on Capital Employed (ROCE) of 20.40%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Alkem Laboratories Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Alkem Laboratories Ltd has a debt-to-equity ratio of 0.12, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Alkem Laboratories Ltd has an Earnings Per Share (EPS) of ₹198.32, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹5,544.5 and P/E ratio of 27.50, investors are paying 27.50 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Alkem Laboratories Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Alkem Laboratories Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Alkem Laboratories Ltd stock, consider: 1) Fundamental Analysis - Review P/E (27.50), ROE (8.46%), debt-to-equity (0.12), and growth rates. 2) Technical Analysis - Check 52-week range (₹4610.00 - ₹5933.50), moving averages, and chart patterns. 3) Valuation - Compare current price (₹5544.50) with book value (₹1002.37) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Alkem Laboratories Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹5,544.5 is 277125x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Alkem Laboratories Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹4610.00 - ₹5933.50). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.12 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,47,779 shares. 5) Valuation Risk - P/E of 27.50 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Alkem Laboratories Ltd operates in the industry with key metrics: P/E ratio of 27.50, ROE of 8.46%, market cap of ₹65,214.34 crores, and dividend yield of 0.83%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.12), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Alkem Laboratories Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹5,544.5, with a 52-week range of ₹4610.00 to ₹5933.50. Based on fundamentals like P/E (27.50), ROE (8.46%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Alkem Laboratories Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹5544.50. 2) Fundamental Deterioration - Declining ROE (currently 8.46%), increasing debt (D/E: 0.12), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Alkem Laboratories Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.83%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.